Neurocrine: FDA OKs INGREZZA for Chorea Associated With Huntington's

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA^® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD).¹ INGREZZA is the only selective vesicular monoamine transporter 2 (VMAT2) inhibitor that offers an effective starting dosage that can be adjusted by a patient's healthcare provider based on response and tolerability, with no complex titration.¹ Only INGREZZA offers simple dosing that is always one capsule, once daily.

https://www.biospace.com/article/releases/neurocrine-biosciences-announces-fda-approval-of-ingrezza-valbenazine-capsules-for-the-treatment-of-chorea-associated-with-huntington-s-disease/